A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With Paget's Disease of Bone

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00480662

Enrollment

Registered

2007-05-31

Start date

2001-10-31

Completion date

2002-10-31

Last updated

2024-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paget's Disease of Bone

Keywords

Paget's bone disease

Brief summary

To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.

Interventions

DRUGalendronate

Duration of Treatment : 6 Months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Male or female, ages 18 to 90 years with a diagnosis of Paget's bone disease

Exclusion criteria

* Patient cannot stand or sit upright for at least 30 minutes * Patient has difficulty swallowing or problems with digestive system

Design outcomes

Primary

Measure	Time frame
Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months	—

Secondary

Measure	Time frame
MK0217 will be safely tolerated	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026